Current state of screening for bladder cancer.

Abstract

Bladder cancer is the fourth most commonly diagnosed cancer in men and the eighth most common cancer in women in the USA. Efforts to reduce mortality from bladder cancer must focus on three areas: prevention, development of effective therapies for muscle-invasive and metastatic disease, and early detection of potentially invasive lesions while they are still superficial and amenable to less morbid, but still effective, treatments. As more effective therapies for metastatic transitional cell carcinoma are not on the immediate horizon and preventive measures (except for smoking cessation) have been disappointing, if we are to reduce this disease's morbidity and mortality rates significantly, early detection strategies need to be improved and implemented. The goal of screening for any type of cancer is to detect the disease in its early stages in order to increase the chances for cure or prolongation of life (before micro or gross metastases occur). Since all patients who die of bladder cancer do so from metastases and since almost all patients with metastases have muscle-invading cancers appearing as the first bladder cancer event, diagnosing cancers destined to become muscle invading before they actually are should reduce bladder cancer mortality. This special report reviews the current state of bladder cancer screening in the USA.

• Authors: Ralph Madeb, Dragan Golijanin, Joy Knopf, Edward M Messing
• Journal: Expert review of anticancer therapy (Expert Rev Anticancer Ther) Vol. 7 Issue 7 Pg. 981-7 (Jul 2007) ISSN: 1744-8328 [Electronic] England
• PMID: 17627458 (Publication Type: Journal Article, Review)

Topics

• Humans
• Mass Screening
• Urinary Bladder Neoplasms (diagnosis, epidemiology, therapy)